MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ — Boston Scientific Corporation (BSX) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the Vercise Gevia™  Deep Brain Stimulation (DBS) System to be used in a full-body magnetic resonance imaging (MRI) environment.1  This system, with the Vercise Cartesia™ Directional Lead, is designed to treat the symptoms of Parkinson’s Disease (PD) by delivering precisely targeted electrical stimulation in the brain to provide optimal symptom relief and better control of unwanted side effects.

source https://finance.yahoo.com/news/boston-scientific-announces-fda-approval-213900546.html?.tsrc=rss